Remove how-we-partner
article thumbnail

Reimagining CRO Partnerships: The Emerging Preference for Midsize Organizations

Worldwide Clinical Trials

As the clinical research landscape continually evolves, the choice of a Contract Research Organization (CRO) partner can significantly impact the success of drug development programs. Discover how Worldwide is positioned to meet your needs with agility, expertise, and a truly personalized approach.

article thumbnail

A Reflection on Shared Moments of Strength and Progress in the Rare Disease Communities

Worldwide Clinical Trials

For others, this rare day is aptly the day we honor rare disease communities. At Worldwide, we are dedicated to amplifying the voices of those directly impacted by rare diseases — patients, caregivers, family members, advocates, and healthcare professionals alike. We were overwhelmed by how excited the community was to participate!

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

March 28, 2024: Health Equity Core Provides Reference for Equitable Language in Pragmatic Trials

Rethinking Clinical Trials

We hope that this cheat sheet serves as a valuable tool for researchers and partners striving toward fostering health equity,” she said.

Trials 215
article thumbnail

GenScript ProBio and RVAC partner for Covid-19 vaccine pDNA

Pharmaceutical Technology

GenScript ProBio CEO Dr Brian Min said: “We are delighted to enter into this strategic partnership with RVAC Medicines. To support the mRNA initiatives, RVAC Medicines will continue to partner with GenScript ProBio for the clinical-stage development and commercial stage of its candidates.

article thumbnail

Danaher and University of Pennsylvania partner for cell therapies

Pharmaceutical Technology

Danaher Science and Technology Innovation vice-president Vanessa Almendro said: “Our understanding of science is evolving faster than ever, but to efficiently translate these discoveries into potentially life-changing therapies, we need an equivalent acceleration in manufacturing innovation. “We

article thumbnail

RVAC and University of Pennsylvania to develop mRNA vaccines

Pharmaceutical Technology

Under the deal, Penn Perelman School of Medicine Vaccine Research Roberts Family Professor Drew Weissman and his laboratory will partner with RVAC Medicines for the development and optimisation of mRNA vaccine candidates that can induce immune tolerance in the body.

article thumbnail

MD Anderson and Xilis partner to expedite new cancer therapies development

Pharmaceutical Technology

Xilis CEO and co-founder Dr Xiling Shen said: “Our research suggests the MOS platform has the potential to offer new capabilities and to improve the efficiency of developing innovative drugs and cell therapies over current xenograft and organoid models, which we hope will bring medicines to patients more quickly. “We